Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Amplia Therapeutics ( (AU:ATX) ).
Amplia Therapeutics has announced an additional confirmed partial response in its ACCENT trial, which evaluates the efficacy of narmafotinib combined with standard chemotherapies in advanced pancreatic cancer patients. This brings the total confirmed partial responses to 16, indicating a promising objective response rate of 29% among trial participants, potentially enhancing the company’s position in the oncology sector.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company targets fibrotic cancers such as pancreatic and ovarian cancer, as well as chronic diseases like idiopathic pulmonary fibrosis (IPF).
Average Trading Volume: 4,965,814
Technical Sentiment Signal: Buy
Current Market Cap: A$85.35M
See more data about ATX stock on TipRanks’ Stock Analysis page.